Last reviewed · How we verify
AP301
At a glance
| Generic name | AP301 |
|---|---|
| Sponsor | Alebund Pharmaceuticals |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China (PHASE3)
- AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia (PHASE3)
- Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS (PHASE2)
- A Pharmacodynamic Effect Study of AP301 in Healthy Volunteers (PHASE1)
- A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients (PHASE2)
- Study in Intensive Care Patients to Investigate the Clinical Effect of Repetitive Orally Inhaled Doses of AP301 on Alveolar Liquid Clearance in Acute Lung Injury (PHASE2)
- Study in Intensive Care Patients Regarding the Effect of Inhaled AP-301 After Primary Graft Dysfunction After Lung Transplantation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AP301 CI brief — competitive landscape report
- AP301 updates RSS · CI watch RSS
- Alebund Pharmaceuticals portfolio CI